Ribo Life Science Successfully Debuts on Hong Kong Main Board, Marking a Milestone in siRNA Therapy Ribo Life Science Co., Ltd. has made a triumphant entry onto the Hong Kong Stock Exchange Main Board, signaling a significant advancement in siRNA therapeutics. This momentous step boosts the biopharmaceutical sector.

Ribo Life Science Successfully Debuts on Hong Kong Main Board, Marking a Milestone in siRNA Therapy #Hong_Kong #siRNA_therapy #Hong_Kong_Stock_Exchange #Ribo_Life_Science

Kalexo Bio: A New Era in siRNA Therapy for Cardiovascular Health Mabwell and Aditum Bio have joined forces to create Kalexo Bio, aiming to advance siRNA therapy for cardiovascular disorders through innovative research.

Kalexo Bio: A New Era in siRNA Therapy for Cardiovascular Health #None #siRNA_therapy #Aditum_Bio #Mabwell_Biotech

Rona Therapeutics Secures FDA IND Clearance for RN0361: A Novel siRNA for Hypertriglyceridemia Management Rona Therapeutics has announced FDA IND clearance to advance RN0361, a targeted siRNA therapy for managing hypertriglyceridemia in patients after promising Phase 1 results.

Rona Therapeutics Secures FDA IND Clearance for RN0361: A Novel siRNA for Hypertriglyceridemia Management #Shanghai #USA #Rona_Therapeutics #RN0361 #siRNA_therapy